Publication | Closed Access

Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition

Resistant HeadOncologyNeck Cancer CellsXct InhibitionMedicineHead And Neck CancerAnti-cancer AgentCancer TreatmentNeck OncologyPharmacologyCell BiologyTreatment ResistanceCancer Research